3. Pirkanmaa Hospital District – Anne Kahiluoto3 10.02.15
Introduction
The working group of the Ministry of Social Affairs and Health
proposes that the Finnish comprehensive cancer center comprise a
national coordinating centre and five regional centres which could
function in close association with existing university hospitals and
the catchment areas for providing specialist care.
Financing: Initially, operations would need to be funded mainly from
the state budget and would require funding from a main title of
expenditure of the Ministry of Social Affairs and Health for a
minimum period of three years.
The better the center is able to integrate nationally diagnostics and
care with high quality research and teaching, the more significant
Comprehensive Cancer Center Finland’s (FICAN) added value will
be. FICAN will ensure equitable access to high quality care for
cancer patients in Finland beyond 2020.
4. Pirkanmaa Hospital District – Anne Kahiluoto4 10.02.15
Introduction
Comprehensive Cancer Center Finland (FICAN) = national
coordinating center (Helsinki) and five regional centres (Helsinki,
Kuopio, Oulu, Tampere, Turku)
The cancer center will ensure a high quality treatment to Finnish
cancer patients with comparable and cost-effective care transition.
The number of cancer patients is increasing and the cancer
treatment becomes more and more individual
Cancer diseases are becoming one of the most important chronic
diseases worldwide
5. Pirkanmaa Hospital District – Anne Kahiluoto5 10.02.15
Introduction
In Finland, one in four deaths is caused by cancer
The rate of cancer is increasing every year, with the population
living longer and the aging of the baby-boom generation will
triple cancer costs from 2004 to 2020 (EUR 1.5 billion / year)
The aim is individually tailored therapies (personalized
medicine)efficiently and effectively
Cost-effective cancer treatments can be developed only by
integrating treatment to clinical and translational research
To achieve aims integrated care lines are needed
The response to challenges has been Comprehensive Cancer
Centers, which integrate cancer treatment and research past 50
years in the US (42 centers, Europe 7)
6. Pirkanmaa Hospital District – Anne Kahiluoto6 10.02.15
Introduction
Our multi-disciplinary treatment team consists of different types of
expertise, which addresses the patient's disease: surgery,
chemotherapy, radiation therapy, pathology, genetics, imaging,
palliative care, psychosocial support and rehabilitation
According to international statistics the cancer treatment results in
our country are in the level of high international standard, but rapidly
increasing of research and its exploitation set new requirements for
the implementation of cancer treatment
By using molecular biology and cell biology methods more and more
growth path errors will be found in cancers. Errors can be affected
by the regulation of new drugs
Scientists may not have found cures for all forms of cancer, but
researchers have discovered numerous ways to treat and manage
many of the more than 200 variations of this disease
7. Pirkanmaa Hospital District – Anne Kahiluoto7 10.02.15
What is TAMCAN?
The task is to promote cancer treatment, research and training
Know-how especially in the wide-ranging prostate and breast cancer study
Supports also other types of cancer research and high-quality care
Phase I-II center (early-stage clinical trials are at a low level for the future)
Produces research services, and develops new innovations in translational
research (forms a bridge between basic research and patient care) in
cancer treatment and prevention
The aim is that every tenth patient visit should be associated to research
TAMCAN organizes high-quality research training for catchment areas as
well as nationally and internationally, in conjunction with the University and
the University of Applied Sciences
New drugs given to patients are research based
8. Pirkanmaa Hospital District – Anne Kahiluoto8 10.02.15
Operations and customers
The main customer groups are: Pirkanmaa Hospital District's
municipalities and patients, the catchment areas of the central
hospitals (Pirkanmaa, Lahti, Hämeenlinna, Vaasa), pharmaceutical
industry, surgery, radiotherapy and diagnostic equipment
manufacturers, domestic and international research community and
patient organizations
Clinical cancer trials save approximately 1.5 million euros annually
9. Pirkanmaa Hospital District – Anne Kahiluoto9 10.02.15
Objectives
TAMCAN combines:
• basic
• translational
• clinical
• public health
• scientific research and service system in cancer prevention
• screening
• diagnostics
• treatment and rehabilitation with development.
Finland's leading cancer research center in the overall patient
treatment and on the top of international level, and in other selected
research areas at the good international level by the year 2020.
National Center of the Cancer education
10. Pirkanmaa Hospital District – Anne Kahiluoto10 10.02.15
Phase I-II trial center
To investigate the first time cancerdrug effects in humans to
molecule drug absorption, distribution, metabolism, or excretion of
the human body
The trials is to find treatments that are more effective in controlling
cancer with fewer side effects
Small number of patients in trials
The intention is to carry out research projects, which are in Finland
scientifically necessary
Development of drugs that affect specific targets in the cancer cell is
important. Clinical trials validate the efficacy of these drugs
To develop more effective therapy to different type of cancers
personalized medicine
11. Pirkanmaa Hospital District – Anne Kahiluoto11 10.02.15
Phase I-II trial center
Patients are mainly from Finland, but also from Estonia and Russia
New and modern specialization to medical oncology and radiation
therapy, clinical hematology and pharmacology, as well as
specialized gynecological oncology
Studies can allow participants to benefit from the newest treatments
for several years before they become available at a pharmacy
First in Finland
Situated in oncology ward with four beds
12. Pirkanmaa Hospital District – Anne Kahiluoto12 10.02.15
Staff
Employed by a hospital or university
Phase I-II- trialcenter hospital staff: 2 doctors, four research nurses,
research coordinator, research assistant
Our medical staff have close ties to prominent hospitals and current
cancer research, and we bring those breakthrough advances to our
regional centers to progress the level of care
13. Pirkanmaa Hospital District – Anne Kahiluoto13 10.02.15
Success Factors
Services that support Clinical studies can be implemented uniformly
with the other national centers and international centers
14. Pirkanmaa Hospital District – Anne Kahiluoto14 10.02.15
What are the biggest barriers to moving
cancer research forward faster?
By far our greatest barrier is the lack of money and resources going
into research. Many research ideas or grants that should be funded
do not get funded due to lack of money.
A second major issue is the lack of adults participating in cancer
clinical treatment trials.
15. Pirkanmaa Hospital District – Anne Kahiluoto15 10.02.15
Organization
The organization of TAMCAN consists of board of TAMCAN,
scientific expert group and board of directors all working in Tampere
university hospital or in Tampere university.
16. Pirkanmaa Hospital District – Anne Kahiluoto16 10.02.15
Schedule
Phase I-II Research Center 1/2015
Extension 1/2016
